| Some Common Protocols | |
| Breast cancer | v FAC: fluorouracil + doxorubicin + and cyclophosphamide |
| v CMF: cyclophosphamide + methotrexate + fluorouracil | |
| v FEC: fluorouracil + epirubicin + cyclophosphamide | |
| v AC: doxorubicin + cyclophosphamide | |
| v TC: docetaxel + cyclophosphamide | |
| v TA: docetaxel + Adriamycin | |
| v TCH: docetaxel + cyclophosphamide + HERCEPTIN® | |
| v PH: paclitaxel + HERCEPTIN® | |
| v AC →TH (Adriamycin + cyclophosphamide) then TAXOTER® + HERCEPTIN® | |
| Lung cancer | v Platinum compounds, taxanes, gemcitabine, & etoposide are used. |
| v CP: cisplatin + paclitaxel | |
| v GC: gemcitabine + cisplatin | |
| v DC: docetaxel + cisplatin | |
| v PCb: paclitaxel + carboplatin | |
| v EC: etoposide + cisplatin | |
| Colorectal cancer | v FOLFOX or FLOX: fluorouracil + leucovorin + oxaliplatin |
| v FOLFIRI: fluorouracil + leucovorin + irinotecan | |
| v IROX: irinotecan + oxaliplatin | |
| v CapOX: capecitabine + oxaliplatin | |
| v XELOX: XELODA® (capecitabine) + oxaliplatin | |
| v Bevacizumab, cetuximab, or panitumumab can be added to previous protocols. | |
| Brain tumors | v Carmustine (BCNU), lomustine (CCNU), temozolamide, procarbazine, & bevacizumab. |
| v PCV: procarbazine, CCNU, & vincristine. | |
| Acute lymphoblastic leukemia (ALL) | v Acute lymphoblastic leukemia (ALL) is the main form of leukemia in childhood, and it is the most common form of cancer in children. |
| Agents active against this form: | |
| v Methotrexate, corticosteroids, 6-mercaptopurine, cyclophosphamide, vincristine, daunorubicin, and asparaginase. | |
| Adult Leukemia | v Acute myelogenous leukemia (AML) is the most common leukemia in adults. |
| v Cytarabine + anthracyclines (idarubicin) → remission in about 70% of cases. | |
| Chronic myelogenous leukemia (CML) | v Arises from a chromosomally abnormal hematopoietic stem cell in which a balanced translocation between the long arms of chromosomes 9 and 2. |
| v BCR-ABL tyrosine kinase inhibitors: imatinib, nilotinib, & dasatinib are effective. | |
| v Other alkylating agents, hydroxy urea, & interferon alpha can be used. | |
| Chronic lymphocytic leukemia (CLL) | v Chlorambucil and cyclophosphamide are the two most widely used alkylating agents for this disease. |
| v COP: Cyclophosphamide + vincristine (oncovine) + prednisone. | |
| v CHOP: as the previous + doxorubicin. | |
| v Rituximab: anti CD-20 MAB. | |
| Hodgkin’s lymphoma | v MOPP: mechlorethamine + vincristine (oncovin) + procarbazine + prednisone. |
| v ABVD: Adriamycin (doxorubicin) + bleomycin + vinblastine + dacarbazine. | |
| Non-Hodgkin’s lymphoma | v CHOP: cyclophosphamide + doxorubicin + vincristine (oncovin) + prednisone. |
| v Rituximab may be added to the previous regimen. | |
| Multiple myeloma (MM) | v MP: melphalan + prednisone |
| v VAD: vincristine + doxorubicin + dexamethasone | |
| v Lenalidomide & bortezomib are used in MM. | |
|
|
